


Product data sheet



MedKoo Cat#: 319733 Name: Rafigrelide CAS: 1029711-88-3 Chemical Formula: C ₁₂ H ₁₁ Cl ₂ N ₃ O Exact Mass: 283.0279 Molecular Weight: 284.14		
Product supplied as:	Powder	
Purity (by HPLC):	≥ 98%	
Shipping conditions	Ambient temperature	
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks.	

Product description:

Rafigrelide is a platelet aggregation inhibitor. Rafigrelide treatment prolonged clot formation time and reduced clot strength. Platelets play a central role in atherothrombotic events.

2. CoA, QC data, SDS, and handling instruction

SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
DMSO	2.84	10

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.52 mL	17.60 mL	35.19 mL
5 mM	0.70 mL	3.52 mL	7.04 mL
10 mM	0.35 mL	1.76 mL	3.52 mL
50 mM	0.07 mL	0.35 mL	0.70 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator

Please refer the product web page under section of “Calculator”

6. Recommended literature which reported protocols for in vitro and in vivo study

In vitro study

To be determined

In vivo study

1. Balasubramaniam K, Viswanathan G, Dragone J, Grose-Hodge R, Martin P, Troy S, Preston P, Zaman AG. Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study. *Thromb Haemost.* 2014 Jul 3;112(1):205-15. doi: 10.1160/TH13-08-0681. Epub 2014 Feb 20. PMID: 24553755.

7. Bioactivity

Biological target:

Rafigrelide is a platelet aggregation inhibitor; it prolongs clot formation time and reduces clot strength.

In vitro activity

To be determined

In vivo activity

This study confirms the platelet-lowering effects of rafigrelide and indicates that rafigrelide has antithrombotic properties under both high and low shear conditions.

Product data sheet



Reference: Thromb Haemost. 2014 Jul 3;112(1):205-15. <https://pubmed.ncbi.nlm.nih.gov/24553755/>

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.